Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients. The KOL event will take place on January 24 at 11 a.m. EST.
Piper Sandler Maintains Overweight on First Solar, Lowers Price Target to $170
Piper Sandler analyst Kashy Harrison maintains First Solar (NASDAQ:FSLR) with a Overweight and lowers the price target from $175 to $170.
